"We would hope that the direct results of the project are useful about our thinking of when amyloid deposition starts and when it's clinically relevant. But what is even more important is that the consortium that we formed, started collaborating on things that go well beyond the initial goals of AMYPAD. And actually, we should further integrate AMYPAD, EPAD and all the European cohorts that are now collaborating and joining forces in analysis of PET/MRI scans, imaging, biomarker but also genetic data. It is something of great value and will contribute to the future of all samples, definitely in Europe and hopefully also globally. ” Frederik Barkhof

"It was an absolute honour to be working so closely with such talented and committed scientists across Europe. It took some time to get our clinical studies going but once recruiting there was a huge amount of momentum in all the centres we worked with. For me a personal highlight over the last six years of AMYPAD has been to witness the incredible impact of biomarker research in the AD field. It is my sincere hope that our AMYPAD consortium has made a positive and significant contribution to further our understanding of the disease but more importantly in the future to possibly managing treatment options as well." Gill Farrar